title: Clear cell and papillary serous endometrial carcinomas: survival in a series of 128 cases.
abstract: OBJECTIVE
  Clear cell (CC) and papillary serous carcinoma (PS) are histotypes at high risk of recurrence. We analyse patients' survival in a retrospective series of 128 CC and PS endometrial cancer cases.
  
  
  METHODS
  All women with a histologically confirmed CC and PS endometrial cancer who underwent primary surgery in five institutions in Lombardy, Italy, were eligible for this study. A total of 77 (60.2 %) were PS endometrial cancer cases, 45 (35.2 %) CC cases and 6 (4.6 %) cases had mixed CC and PS histotype.
  
  
  RESULTS
  54 (42 %) cases were diagnosed at stage I, 10 (8 %) at stage II, 47 (37 %) at stage III and 17 (13 %) at stage IV. Recurrence was observed in 49 cases (38.3 %). The median time at recurrence was 12 months (interquartile range 7-18). The rate of recurrence was 20.3 % in cases at stage I-lI and 56.2 % in cases at stage III-IV (p < 0.0001). With regard to the site of recurrence 24 recurrences were in and 52 outside the pelvis. Finally, the rate of recurrence was 32.6 % (14 cases) in CC cases, 43.1 % (31 cases) in PS cases and 66.7 % (4 cases) in cases with mixed histotype. The 5-year progression-free survival was 59.5 % (67.4 % for CC cases, 55.1 % for PS and mixed cases).
  
  
  CONCLUSIONS
  In this study including CC and PS endometrial cancers, the 5-year survival from surgery was 72.7 % and the 5-year progression-free survival was 59.5 %.
authors.affiliation: Obstetric and Gynecological department, RCCS Ospedale Maggiore Policlinico Mangiagalli Regina Elena Milano, University of Milan, Milan, Italy.
authors.forename: Giovanna
authors.initials: G
authors.lastname: Scarfone
authors.forename: Rita
authors.initials: R
authors.lastname: Secomandi
authors.forename: Fabio
authors.initials: F
authors.lastname: Parazzini
authors.forename: Riccardo
authors.initials: R
authors.lastname: Viganò
authors.forename: Giorgia
authors.initials: G
authors.lastname: Mangili
authors.forename: Luigi
authors.initials: L
authors.lastname: Frigerio
authors.forename: Antonella
authors.initials: A
authors.lastname: Villa
authors.forename: Saverio
authors.initials: S
authors.lastname: Tateo
authors.forename: Elena
authors.initials: E
authors.lastname: Ricci
authors.forename: Giorgio
authors.initials: G
authors.lastname: Bolis
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000401:mortality* / Q000473:pathology / Q000601:surgery / Q000628:therapy; D000368:Aged; D059186:Chemoradiotherapy, Adjuvant; D017024:Chemotherapy, Adjuvant; D018283:Cystadenocarcinoma, Papillary / Q000401:mortality* / Q000473:pathology / Q000601:surgery / Q000628:therapy; D018284:Cystadenocarcinoma, Serous / Q000401:mortality* / Q000473:pathology / Q000601:surgery / Q000628:therapy; D016889:Endometrial Neoplasms / Q000401:mortality* / Q000473:pathology / Q000601:surgery / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome